David Roth MD

PubMed

• Trends of preemptive kidney transplantation in lupus compared to other primary diseases leading to end stage kidney disease in the United States of America.
  Gabriel Contreras, Javier Pagan, Tali Elfassy, Miguel Bandes, Nicolas Bustamante
  Lupus. 2025-05-20
• Transplantation: platform to study recurrence of disease.
  George William Burke, Alla Mitrofanova, Antonio Miguel Fontanella, Francesco Vendrame, Gaetano Ciancio
  Frontiers in Immunology. 2024-01-01
• 1 citations
  Long-term effects of average calcineurin inhibitor trough levels (over time) on renal function in a prospectively followed cohort of 150 kidney transplant recipients.
  Gaetano Ciancio, Jeffrey J Gaynor, Giselle Guerra, Marina M Tabbara, David Roth
  Clinical and Translational Science. 2023-11-01

Journal Articles

• Treatment and management options for the hepatitis C virus infected kidney transplant candidate  
  Dejman A, Ladino M, Roth D, Hemodial Int, 1/22/2018
• End stage kidney disease and the treatment of hepatitis C virus infection  
  Pagan J, Ladino M, Roth D, Current Hepatology Reports, 1/1/2018
• Clinical trials: Treatment of HCV infected patients with advanced kidney disease  
  Ladino M, Roth D, Nat Rev Nephrol, 1/1/2018
• Roux-en-y gastric bypass is an effective bridge to kidney transplantation: results from a single center  
  Thomas I, Gaynor J, Joseph T, De la Cruz N, Sageshima J, Kupin W, Chen L, Ciancio G, Burke G, Mattiazzi A, Roth D, Guerra G, Clin Transpl, 1/1/2018
• How I Treat: Hepatitis C virus infection in patients with ESRD  
  Ladino M, Roth D, Clin J Am Soc Neph, 1/1/2018
• Antibody-mediated rejection implies a poor prognosis in kidney transplantation: Results from a single center  
  Ciancio G, Gaynor J, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Ruiz P, Vianna R, Burke G, Clin Transpl, 1/1/2018
• Transplantation of kidneys from hepatitis C positive donors: How best to use a scarce resource  
  Roth D, Ladino M, J Am Soc. Nephrol., 1/5/2017
• Randomized trial of rATg/daclizamab vs rAtg/Alemtuzamab as dual induction therapy in renal transplantation: Results at 8 years of follow-u  
  Ciancio G, Gaynor J, Guerra G, Sageshima, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Ruiz P, Vianna R, Burke G, Transpl Immunol, 1/1/2017
• Benefits of transplanting kidneys from hepatitis C positive donors into hepatitis C virus infected recipients followed by early initiation of direct acting antiviral t...  
  Bhamidimarri KR, Ladino M, Pedraza F, Guerra G, Mattiazzi A, Chen L, Ciancio G, Kupin W, Martin P, Burke G, Roth D, Transplant Int., 1/1/2017
• Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4/5 chronic kidney disease; clinical, virologic and health-related quality of life out...  
  Bruchfeld A, Roth D, Martin P, Nelson D, Pol S, Londono M, Monsour H, Silva M, Hwang P, Arduino J-M, Robertson M, Nguyen B-N, Wahl J, Barr E, Greaves W, Lancet Gastroenterology and Hepatology, 1/1/2017
• Elbasvir/grazobrevir does not worsen renal function in patients with hepatitis C virus infection and pre-exitsing renal disease  
  Reddy R, Roth D, Bruchfeld A, Hwang P, Haber B, Robertson M, Barr E, Greaves W, Hepatol Res, 1/1/2017
• Impact of direct acting antiviral agents on kidney function in hepatitis C virus infected patients  
  Ladino M, Pedraza F, Roth D, World J Hep, 1/1/2017
• Direct acting antiviral agents for the Hepatitis C virus infected chronic kidney disease population: The dawn of a new era  
  Kusnir J., Roth D., Semin Dial, 1/1/2016
• Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation  
  Gaynor J, Ciancio G, Guerra G, Sageshima J, Roth D, Goldstein M, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Ruiz P, Vianna R, Burke GW, Trans Int, 1/1/2016
• Brief Review: Hepatitis C virus infection in the patient with chronic kidney disease  
  Ladino M, Pedraza F, Roth D, J Am Soc Neph, 1/1/2016
• Cost-effectiveness of elbasavir/grazoprevir use in treatment-na�ve and treatment �experienced patients with hepatitis C virus genotype 1 infection and chronic kidney d...  
  Elbasha E, Greaves W, Roth D, Nwankwo C, J Viral Hep, 1/1/2016
• Multivariable risk of developing new onset diabetes after transplant- result from a single center study of 481 adult, primary kidney transplant recipients  
  Gaynor JJ, Ciancio G, Guerra G, Sageshima J, Hanson L, Roth D, Goldstein M, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Baarba L, Lopez A, Rivas J, Ruiz P, Viann..., Clin Transplant, 1/1/2015
• Single center study of 628 adult primary kidney transplant recipients showing no unfavorable effect of new onset diabetes after transplant  
  Gaynor JJ, Ciancio G, Guerra G, Sageshima J, Hanson L, Roth D, Goldstein M, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Barba L, Lopez A, Rivas J, Ruiz P, Vianna..., Diabetologia, 1/1/2015
• Safety and efficacy of simeprevir plus half-dose sofosbuvir for hepatitis C treatment in end stage renal disease  
  Bhamidimarri K, Czul F, Peyton A, Levy C, O�Brien C, Jeffers L, Hernandez M, Roth D, Schiff E, Martin P, J Hepatol, 1/1/2015
• Grazoprevir plus elbasvir in treatment-na�ve and treatment experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C...  
  Roth D, Nelson D, Bruchfeld A, Liapakis A Silva M, Monsour H, Martin P, Pol S, Londono M, Hassaneim T, Zamor P, Zuckerman E, Wan S, Jackson B, Nguyen B, Robertson M, B..., Lancet, 1/1/2015
• Randomized trial of three induction antibodies in kidney transplantation: Long-term results  
  Ciancio G, Burke GW, Gaynor JJ, Roth D, Kupin W, Rosen A, Cordovilla T, Tueros L, Herrada E, Miller J, Transplantation, 1/1/2014
• Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: A single center observational study  
  Gaynor J, Ciancio G, Guerra G, Sageshima J, Hanson L, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Aminsharifi J, Joshi S, Chediak Z, Ruiz P, Vianna R, Bu..., Transplantation, 1/1/2014
• Kidney allograft survival of African- and Caucasian-American recipients with lupus  
  Contreras G, Li H, Gonzalez-Suarez M, Isakova T, Sciala J, Pedraza F, Mattiazi A, Diaz-Wong R, Sageshima J, Brito Y, Guerra G, Acevedo B, Ali A, Kershaw T, Chen L, Bur..., Lupus, 1/1/2014
• Predictors of reduced tacrolimus dose and trough level through 36 months post-transplant among 578 adult, primary kidney transplant recipients  
  Gaynor J, Ciancio G, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Vianna R, Burke G, Clin. Transplantation, 1/1/2014
• Excessive immunosuppression as a potential cause of poor survival in simultaneous liver/kidney transplantation for hepatitis C  
  Hibi T, Nishida S, Sageshima J, Levi D, Ruiz P, Roth D, Martin P, Okabayashi K, Burke G, Ciancio G, Tzakis A, Transplant Int, 1/1/2014
• Join now to see all

Books/Book Chapters

• Hepatitis C in Renal Disease, Hemodialysis and Transplantation 
  Chapter: Selection and management of Hepatitis C virus infected patients for the kidney transplant waiting list 
  Roth D, Bloom R.Editors: Morales JM.Contrib. Nephro. Karger2012
• Hepatitis C in Renal Disease, Hemodialysis and Transplantation 
  Chapter: Kidney transplantation in the patient with Hepatitis C virus infection 
  Morales JM, Bloom R, Roth DEditors: Morales JM.Contrib. Nephro. Karger2012
• Atlas of Diseases of the Kidney 
  Chapter: Renal disease in patients infected with hepatitis and human immunodeficiency virus 
  Bourgoignie JJ., Rao TKS., Roth D.Editors: R. Schrier.Current Medicine Inc., Philadelphia, PA1999
• Kidney Transplant Rejection 
  Chapter: Hepatitis in the renal allograft recipient 
  Page 627 - 645Roth D., Miller J.Editors: L. Racusen.Marcel DekkerEdition 3rd,1998
• Kidney Transplant Rejection 
  Chapter: Tacrolimus and mycophenolate mofetil as primary immunosuppression for renal allograft recipients 
  Page 519 - 529Ciancio G., Burke GW, Roth D., Zucker K., Esquenazi V., Rosen A., Miller J.Editors: L. Racusen.Marcel DekkerEdition 3rd,1998
• Therapy of Renal Diseases and Related Disorders 
  Chapter: Hepatitis in the renal patient 
  Page 893 - 914Roth D., Perez G.Editors: W. Suki and S. Massry.Kluwer Academic PublishersEdition 3rd,1997
• The Kidney in Liver Disease 
  Chapter: The significance of hepatitis C virus infection in the care of patients with renal diseas 
  Page 151 - 166Roth DEditors: M. Epstein.Hanly and Belfus, Inc.Edition 4th,1996
• Nephrology 
  Chapter: The epidemiology of human immuno-deficiency virus-associated nephropathy 
  Page 384 - 392Bourgoignie JJ., Ortiz-Interian C., Green DF., Jaffe D., Roth D., Pardo V.Editors: M. Hantano.Springer-Verlag, Tokyo, Japan1991
• Int. Yearbook Nephrology 
  Chapter: Renal complications of human immunodeficiency virus-type 1 
  Bourgoignie JJ., Ortiz-Interian C., Green DF., Jaffe D., Roth D., Pardo V.1989
• Clin. Transplantation 
  Chapter: Long-term results of kidney transplantation at the University of Miami 
  Burke G., Esquenazi V., Gharagozloo H., Roth D., StraussEditors: Paul Terasaki.1989
• Renal-genitourinary Disorders: Progression, replacement therapy, growth 
  Chapter: The biologic significance of the mixed lymphocyte kidney culture in humans 
  Page 309 - 332Roth D., Fuller L., Kyriakides G., Esquenazi V., Miller J.Editors: Jose Strauss.University of Miami Press1987
• Acute Internal Medicine 
  Chapter: Severe Electrolyte Abnormalities 
  Page 540 - 559Roth DEditors: L. Gardner.Medical Exam. Publ. Co.1986
• Nephrology and Hypertension 
  Chapter: Disorders of water metabolism 
  Page 1 - 21Roth DEditors: J. Oster.University of Miami1985
• Nephrology and Hypertension 
  Chapter: Dialysis and Transplantation 
  Page 87 - 95Roth D. and Perez GEditors: J. Oster.University of Miami1985
• Proceedings of the Symposium in Acute Renal Failure 
  Chapter: A new model for studying drug induced renal failure. The rat with untreated diabetes mellitus 
  Page 96 - 101Vaamonde C., Teixeria RB., Morales J., Roth D., Kelly J., Alpert H., and Pardo VEditors: Eliahou HE.John Libbey and Co., Tel Aviv, Israel1982
• Nephrology and Hypertension 
  Chapter: The use of drugs in the patient with uremia 
  Page 379 - 397Vaamonde C. and Roth DEditors: JJ. Bourgoignie and C. Vaamonde.University of Miami1981
• Join now to see all

Abstracts/Posters

• The rat with untreated diabetes mellitus: A new model for studying drug-induced nephrotoxicity. Presented at the International Symposium on Nephrotoxicity
  Vaamonde C., Teixeria R.B., Morales J., Roth D., Kelly J., Alpert H., and Pardo V, University of Surrey Guildford, England, 1/1/1981

Lectures

• HCV Infection in the ESRD Patient 
  Orlando, FL - 1/16/2018
• The View from 10,000 feet: A Roadmap for the Nephrologist to take charge of their patients with HCV infection 
  Austin, TX - 1/12/2018
• Chronic HCV and CKD: A Complex Combination 
  Santiago, Chile - 1/30/2017
• Treatment of Hepatitis C Virus in the Patient with End Stage Renal Disease 
  Las Vegas, NV - 1/28/2017
• Impact of Hepatitis C Virus in Chronic Kidney Disease 
  New York, NY - 1/20/2017
• Treatment of the CKD Patient with Hepatitis C Virus Infection 
  Orlando, FL - 1/20/2017
• Impact of HCV and Available Treatment Options for Patients with Kidney Disease 
  Nashville, TN - 1/19/2017
• Hepatitis C Virus Infection in Patients with Kidney Disease 
  Baptist Hospital, Miami, FL - 1/18/2017
• Direct Acting Antiviral Agents for the Treatment of HCV-Infected CKD and ESRD Patients 
  Massachusetts General Hospital, Boston, MA - 1/13/2017
• Hepatitis C Virus Infection in the ESRD Patient 
  Long Beach, CA - 1/11/2017
• Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease: What are the Options? 
  Hoboken, NJ - 1/9/2017
• Trick or Tweat: HCV in the Kidney Transplant Recipient 
  New Orleans, LA - 1/4/2017
• HCV Infection in Patients with Glomerular and Non-glomerular CKD 
  New Orleans, LA - 1/4/2017
• Hepatitis C Virus Infection in Patients with CKD 
  San Juan, Puerto Rico - 1/29/2016
• The Global Impact of Hepatitis C Virus Infection in Patients with Chronic Kidney Disease 
  Boston, MA - 1/28/2016
• Treatment of Hepatitis C Virus in Patients with Chronic Kidney Disease: Challenges and Opportunities 
  Vienna, Austria - 1/22/2016
• Role of HCV Infection in the Progression of Chronic Kidney Disease 
  Chicago, IL - 1/18/2016
• Optimizing Treatment of the HCV Infected CKD Patient 
  Chicago, IL - 1/17/2016
• HCV Treatment in Patients with Renal Failure 
  Boston, MA - 1/14/2016
• The Intersection of Hepatitis C Virus in Liver and Kidney Disease 
  1/14/2016
• Treatment of Hepatitis C in Dialysis Patients 
  Chicago, IL - 1/9/2016
• Impact of Hepatitis C Virus Treatment in Patients with Kidney Disease 
  Philadelphia, PA - 1/5/2016
• Hepatitis C Virus and Glomerulonephritis 
  Miami, FL - 1/3/2016
• C-SURFER: Grazoprevir plus Elbasvir in treatment-naive and treatment experienced patients with Hepatitis C virus genotype 1 infection and chronic kidney disease 
  Vienna, Austria - 1/26/2015
• New Treatment Strategies for CKD Patients with Hepatitis C Virus Infection 
  Miami Beach, FL - 1/23/2015
• Join now to see all